Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations" [Eur J Cancer 207 (2024) 114158].
Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Woelwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J. Kron A, et al. Among authors: kollmeier j. Eur J Cancer. 2024 Oct 29;213:115074. doi: 10.1016/j.ejca.2024.115074. Online ahead of print. Eur J Cancer. 2024. PMID: 39476444 Free article. No abstract available.
Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.
Stephan-Falkenau S, Streubel A, Mairinger T, Blum TG, Kollmeier J, Mairinger FD, Bauer T, Pfannschmidt J, Hollmann M, Wessolly M. Stephan-Falkenau S, et al. Among authors: kollmeier j. Int J Mol Sci. 2023 Jun 23;24(13):10558. doi: 10.3390/ijms241310558. Int J Mol Sci. 2023. PMID: 37445733 Free PMC article.
One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
Hager T, Borchert S, Wessolly M, Mathilakathu A, Mairinger E, Kollmeier J, Mairinger T, Hegedus B, Greimelmaier K, Wohlschlaeger J, Herrmann K, Mairinger FD. Hager T, et al. Among authors: kollmeier j. Int J Mol Sci. 2023 Mar 28;24(7):6356. doi: 10.3390/ijms24076356. Int J Mol Sci. 2023. PMID: 37047331 Free PMC article.
Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany.
Rihs HP, Casjens S, Raiko I, Kollmeier J, Lehnert M, Nöfer K, May-Taube K, Kaiser N, Taeger D, Behrens T, Brüning T, Johnen G; MoMar Study Group. Rihs HP, et al. Among authors: kollmeier j. Biology (Basel). 2022 Dec 14;11(12):1826. doi: 10.3390/biology11121826. Biology (Basel). 2022. PMID: 36552335 Free PMC article.
Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model.
Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, Steinborn J, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Mairinger FD. Borchert S, et al. Among authors: kollmeier j. Int J Mol Sci. 2023 Aug 4;24(15):12426. doi: 10.3390/ijms241512426. Int J Mol Sci. 2023. PMID: 37569808 Free PMC article.
Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients.
Fleischhacker M, Arslan E, Reinicke D, Eisenmann S, Theil G, Kollmeier J, Schäper C, Grah C, Klawonn F, Holdenrieder S, Schmidt B. Fleischhacker M, et al. Among authors: kollmeier j. Diagnostics (Basel). 2023 Jun 21;13(13):2131. doi: 10.3390/diagnostics13132131. Diagnostics (Basel). 2023. PMID: 37443525 Free PMC article.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Wölwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J. Kron A, et al. Among authors: kollmeier j. Eur J Cancer. 2024 Aug;207:114158. doi: 10.1016/j.ejca.2024.114158. Epub 2024 Jun 14. Eur J Cancer. 2024. PMID: 38941869 Free article.
114 results